Therapeutic Purpose of Phthalazolum

Phthalazolum (Phthalylsulfathiazole) is an antimicrobial agent belonging to the sulfonamide group. It is specifically designed for the treatment of infections localized within the gastrointestinal tract. Unlike many other antimicrobials, this substance is characterized by its very low systemic absorption; it remains largely within the intestine, where it gradually breaks down to release the active component, sulfathiazole.

Main Uses and Indications

The primary application of Phthalazolum is in the management of bacterial infections of the digestive system. It is commonly utilized for the following conditions:

• Bacillary Dysentery: Treatment of acute and chronic forms of dysentery caused by susceptible bacteria.
• Gastroenteritis and Enterocolitis: Management of inflammatory conditions of the stomach and intestines resulting from bacterial activity.
• Foodborne Illnesses: Addressing intestinal distress caused by the ingestion of contaminated food or water.
• Colitis: Treatment of inflammation of the colon when a bacterial origin is identified.
• Preoperative and Postoperative Care: Used in abdominal surgery to reduce the risk of purulent complications by lowering the bacterial load within the intestinal lumen.

Benefits of Local Action

The clinical utility of Phthalazolum is derived from its unique pharmacokinetic profile. Because it is minimally absorbed into the bloodstream, the medication offers specific benefits:

• High Local Concentration: The drug achieves high concentrations directly at the site of infection in the large intestine.
• Reduced Systemic Impact: Since the majority of the drug does not enter the general circulation, it has a lower impact on internal organs such as the kidneys and liver compared to systemic sulfonamides.
• Bacteriostatic Effect: It effectively inhibits the growth and reproduction of a wide range of microorganisms, including Escherichia coli, Shigella, and various strains of streptococci and staphylococci found in the gut.

Who Can and Cannot Use Phthalazolum?

Eligibility to use Phthalazolum (Phthalylsulfathiazole) is strictly defined by regulatory authorities and centers on the user's immune status, organ function, and physiological state.

Absolute Contraindications

Individuals who must not use this medication include those with:

• Hypersensitivity to Sulfonamides: A known allergy or history of adverse reaction to Phthalylsulfathiazole or any other sulfonamide-containing medicine.
• Severe Organ Impairment: Documented severe hepatic dysfunction (liver failure) or severe renal dysfunction (kidney failure).

Restricted and Conditional Use

Use of Phthalazolum in certain populations requires specific medical assessment, as its safety and use are not broadly established or may pose risks:

• Pregnancy and Lactation: Use during pregnancy is restricted and necessitates a formal benefit-risk assessment. Use while breastfeeding is generally not recommended due to potential infant exposure.
• Pediatric Patients: Use in children often lacks sufficient established data, and regulatory labels may classify it as use not established below a certain age threshold.

Interactions with other Medicines and Products

Official regulatory documents define the interaction profile of Phthalazolum based on the systemic effects of its active sulfonamide component, Sulfathiazole, and its local action in the gut.

Documented Interaction Patterns

Interacting Substance Class	Interaction Type	Official Regulatory Outcome
Oral Anticoagulants (e.g., Warfarin)	Pharmacokinetic/Protein Binding	Potentiation of the anticoagulant effect, requiring close monitoring of coagulation parameters.
Antidiabetic Medications (Sulfonylureas, Insulin)	Pharmacodynamic	Increased risk or severity of hypoglycemia (additive effect on blood glucose reduction).
Bile Acid Sequestrants (e.g., Cholestyramine)	Absorption Interference	Decreased absorption of Phthalazolum, resulting in reduced exposure.

Restrictions and Cautions

Co-administration with Bile Acid Sequestrants requires a separation of administration timing to avoid the documented reduction in Phthalazolum availability. Pharmacodynamic interactions are also documented with Cyclosporine, which carries an increased risk of renal failure when combined. Furthermore, Phthalazolum is documented to decrease the renal excretion rate of Benzylpenicillin.

Interaction risks are officially noted to be heightened in patients with severe hepatic or renal dysfunction due to impaired elimination of the active sulfonamide component.

Selective Inhibition of Bacterial Folic Acid Synthesis

Phthalazolum is a prodrug that undergoes hydrolysis in the lower gastrointestinal tract to release its active metabolite, sulfathiazole. Sulfathiazole acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase ( DHPS). This enzyme is essential for initiating the synthesis of folic acid ( tetrahydrofolic acid) by incorporating PABA ( para-aminobenzoic acid). By binding to the active site, sulfathiazole prevents the natural substrate PABA from being utilized, effectively blocking a core metabolic pathway.

Bacteriostasis via Genetic Replication Arrest

The resulting deficiency in folic acid prevents the synthesis of crucial purine and pyrimidine building blocks for DNA and RNA. This deficit arrests bacterial cell division and proliferation, a physiological outcome known as bacteriostasis. This mechanism exhibits selectivity, as human cells utilize preformed folic acid acquired through the diet, rather than synthesizing it through the targeted DHPS pathway.

How to Use Phthalazolum

Phthalazolum (Phthalylsulfathiazole) administration is designed to ensure its primary action is localized within the gastrointestinal tract. This oral administration route is key to the drug's purpose as an anti-infective.

---

Administration and Dosing Regimens

Standard protocols follow a specific, multi-day, dose-tapering schedule for adult patients. The medication is generally provided as a tablet or capsule, and must be taken with water, typically in divided doses throughout the day.

Parameter	Administration Guideline
Route of Administration	Oral ingestion is the designated route.
Adult Dosing Schedule	A stepped reduction in dosage is followed over the course of treatment. An initial phase on Day 1 may involve up to 1 g every 4 hours, followed by systematic reductions (e.g., 1 g every 6 hours, then every 8 hours) on subsequent days.
Frequency Pattern	Administration is multiple times per day (e.g., every 4 to 8 hours) to ensure consistent presence in the intestinal lumen.
Course Duration	The treatment is a short, fixed duration, generally lasting between five and seven days and requires completion of the prescribed tapering schedule.

---

Population-Specific Instructions

Dosage for pediatric patients is not standardized by fixed dose. Instead, the administration guidelines require the dose to be calculated based on the child’s body weight and age. For instance, children over three years typically receive mg/kg doses every four hours, while those under three years receive mg/kg doses every eight hours. This weight-based calculation ensures adherence to established prescribing standards.

Research evidence / Overview of studies for Phthalazolum

Research involving Phthalylsulfathiazole, the active component, explored its role within the digestive system. Research examined what has been observed so far in specific research scenarios, focusing on the conditions for which it was studied.

---

Evidence for Use in Acute Intestinal Infections

The research base for Phthalylsulfathiazole in acute infectious conditions includes Early Clinical Evaluations, Case Series, and Observational Studies. These studies were conducted during periods of increased symptom activity in patients with infectious enterocolitis and bacterial dysentery.

Research examined outcomes related to physical discomfort and outcomes describing episodic or acute changes in the gut environment. Studies monitored results like the change in the frequency of loose stools, patient-reported outcomes describing perceived discomfort in the abdomen, and measurements of bacteria in the colon. These studies focused on episodes where symptoms become more noticeable.

Findings describe patterns observed in the studies, which largely focused on short-term observation periods, typically lasting 5 to 10 days, to assess responses over defined time intervals. Studies report how symptoms evolved in the observed populations over defined time intervals. However, certainty remains low, and research so far indicates that the data are predominantly derived from older research settings.

---

Evidence Supporting Preoperative Intestinal Preparation

Clinical studies and comparative trials were studied for the role of Phthalazolum as a supportive measure before certain intestinal procedures. Research explored its use in adult patients scheduled for colorectal and other gut surgeries. This compound was commonly evaluated as one component within a structured, multi-drug preparation regimen.

Studies monitored outcomes monitoring physiological strain or stress and post-operative complication rates. Research describes how the compound was applied in a surgical setting. The research highlights changes measured during the study period, examining its inclusion in protocols to assess post-operative infection rates.

Because the compound was usually studied in combination with other treatments, comparative evidence is lacking to isolate findings. Findings describe group patterns, not personal outcomes, as study results reflect the specific conditions under which they were conducted as part of a regimen.

---

Research Gaps and What Remains Uncertain

The overall evidence quality varies across studies, and some key limitations persist in the research record for Phthalazolum. A significant gap is the reliance on older research; modern Randomized Controlled Trials (RCTs) are not widely available in regulatory summaries for current labeling.

Furthermore, studies involving surgical preparation often used the compound in a combination protocol, meaning the specific influence of Phthalazolum alone on outcomes is uncertain. Comparative evidence is lacking against newer antimicrobial therapies. Overall, the research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain — regarding its full clinical profile.

Key Studies & References

1. Anatomical Therapeutic Chemical (ATC) Classification System: A07AB02
2. Review of Sulfonamide Use in Infectious Diarrhea: Evidence Synthesis of Early Clinical Data

Common questions about Phthalazolum (FAQ)

Q: What is the main difference between Phthalazolum and standard antibiotics?

Phthalazolum is a sulfonamide antibiotic designed for minimal systemic absorption into the bloodstream. This specialized design means it is intended to act primarily within the gastrointestinal (GI) tract to treat infections locally, distinguishing it from antibiotics that are widely distributed throughout the body.

Q: Is Phthalazolum used for all types of diarrhea, or only specific kinds?

Official indications list use for infectious intestinal conditions such as bacterial dysentery and enterocolitis. Regulatory indications describe the drug's intended use for conditions related to bacterial activity in the gut.

Q: Are there different strengths or formulations of Phthalazolum?

According to official product information, Phthalazolum is primarily supplied as a tablet for oral administration. Regulatory labels specify the exact commercial strengths that are available to prescribers.

Q: Does Phthalazolum treat the symptoms or the cause of the problem?

The drug’s mechanism is classified as bacteriostatic, meaning it works by inhibiting bacterial growth and proliferation, which addresses the underlying cause of the infection. This action then supports the resolution of associated symptoms.

Q: Is Phthalazolum considered safe for long-term use?

Regulatory documents define a fixed, short treatment duration for Phthalazolum, typically lasting only 5 to 7 days. This prescribed course indicates that the drug is not authorized for long-term or chronic administration.

Q: What does official research say about Phthalazolum use in children?

Official regulatory labels often state that the safety and effectiveness of Phthalazolum in certain pediatric populations, especially children below a specified age threshold, is not established. Regulatory labels note that use in children requires specific medical guidance due to the lack of established data.

Q: Do you need to finish the entire course of Phthalazolum even if you feel better?

Official instructions emphasize that the entire prescribed course and tapering schedule must be completed. This approach is intended to support effective treatment and reduce the potential for treatment failure or resistance development.

Q: What is the difference between Phthalazolum and sulfa drugs used for UTIs?

The core difference lies in their design for absorption. Phthalazolum is specifically formulated for low systemic absorption to keep its action localized to the gastrointestinal tract. In contrast, sulfa drugs for urinary tract infections (UTIs) are designed to be highly absorbed into the bloodstream.

Q: Are there any specific vitamins or minerals that Phthalazolum interacts with?

Regulatory documents note a potential safety consideration regarding folate-related Vitamin B deficiency, which is linked to the drug class's influence on the folic acid synthesis pathway. This is listed as an adverse effect associated with the drug's mechanism of action.

Q: Is Phthalazolum sold under any other brand names internationally?

Phthalazolum is the name for the active substance, Phthalylsulfathiazole. Regulatory and public databases indicate that the substance may be marketed under various local or international brand names in different regions around the world.

Q: What happens if a dose of Phthalazolum is missed?

Regulatory labels contain specific, non-personalized instructions for managing missed doses. These instructions outline the procedure to follow based on the time remaining until the next scheduled dose, ensuring consistency in administration.

Q: Can Phthalazolum be taken at the same time as antacids?

Official warnings advise caution and suggest separating the administration times for Phthalazolum and antacids. This measure is intended to reduce the risk of impaired absorption of the antibiotic, which could potentially reduce its efficacy.

Q: Are there any known food groups that interfere with how Phthalazolum works?

General labeling for this drug class notes a potential interaction with foods or supplements high in folate. This caution relates to the drug's mechanism of action on the bacterial folic acid synthesis pathway.

Q: Can Phthalazolum be crushed or split if needed?

Official administration instructions specify whether the tablets can be altered before swallowing. Tablets should be swallowed as directed unless regulatory instructions indicate otherwise (e.g., if the tablet is scored or specific crushing is noted).

Q: Does taking Phthalazolum affect birth control pills?

Regulatory labels for sulfonamides often state that they may reduce the effectiveness of oral contraceptives. When a reduction in effectiveness is noted, the product information indicates the need for an additional or alternative non-hormonal method of contraception during use.

Q: Are headaches a commonly reported side effect of Phthalazolum?

Regulatory safety profiles for sulfonamides frequently list headache as a reported adverse reaction. Official documents categorize this as a common or uncommon effect seen in some patients.

Q: Can someone who is lactose intolerant take Phthalazolum tablets?

Official regulatory labels list all inactive ingredients (excipients) used in the formulation of the tablet. This information is provided to allow individuals to check for ingredients like lactose that may trigger an intolerance or allergy.

Q: Is Phthalazolum known to cause sun sensitivity?

Regulatory documents frequently list photosensitivity (sun sensitivity) as a potential adverse reaction, particularly related to the skin and subcutaneous tissue. This is a recognized safety consideration for the sulfonamide drug class.

Q: Does Phthalazolum interact with alcohol in a negative way?

Official product information for this drug class typically states that the use of alcohol is not recommended during treatment. This is due to the potential for an adverse reaction, sometimes referred to as a disulfiram-like effect.

Q: Are there special warnings for elderly patients using Phthalazolum?

Regulatory labels commonly include special monitoring requirements or dosage adjustments for elderly patients. This is often focused on those with pre-existing renal (kidney) or hepatic (liver) impairment, which can affect the drug's elimination.

Q: What is the shelf life of Phthalazolum tablets?

Official labeling guarantees the drug's full potency and safety only until the printed expiration date. Compliance with specified storage conditions (e.g., controlled room temperature, protection from moisture) is required to ensure the drug maintains its quality until that date.

Q: Does Phthalazolum interact with common pain relievers like ibuprofen?

Regulatory labels may warn against combining sulfonamides with other drugs that carry a risk of hematological or renal toxicity (such as NSAIDs). This caution exists due to the potential for additive risk.

Q: Has Phthalazolum been studied in connection with C. difficile infection?

Regulatory labels for this drug class include a warning for antimicrobial-associated pseudomembranous colitis. This condition is known to be caused by C. difficile infection; the inclusion of this warning in the label describes a potential serious adverse effect associated with antimicrobial use.

Q: What happens if Phthalazolum is taken past its expiration date?

Official labeling only guarantees the full potency and safety of the medicine until the printed expiration date. Using the product after this date may result in unknown potency loss or changes in stability.

Q: Do official patient leaflets warn about driving while taking Phthalazolum?

If adverse reactions such as headache or dizziness are listed in the safety profile, regulatory labels may caution patients about performing tasks that require complete mental alertness, such as driving or operating machinery.

Q: Can Phthalazolum be taken on an empty stomach?

Regulatory labels provide specific instructions on the administration of the tablet. These official guidelines state whether the drug should be taken with or without food for optimal local action in the gut and to improve patient tolerance.

Q: What are the symptoms of an overdose of Phthalazolum?

Regulatory labels contain a dedicated section detailing the expected signs and symptoms of an overdose. This information is included in official documents to guide medical professionals on appropriate management measures in case of acute toxicity.

Q: Is it safe to take herbal supplements while on Phthalazolum?

Official labels frequently carry a general caution against combining supplements, including herbal products, with prescription medicine. This is due to the potential for unknown interactions that could alter the drug's effect or increase the risk of adverse reactions.

Q: How long does Phthalazolum stay in the body after the last dose?

Pharmacokinetics sections in regulatory documents report the drug's elimination half-life ( t1/2). This technical value provides the basis for determining how long the substance, or its active metabolite, remains detectable in the body.

Q: Does Phthalazolum make you feel sleepy or tired?

Regulatory safety profiles list the potential common and uncommon effects of the drug. These official documents may specifically mention fatigue, dizziness, or drowsiness as possible adverse reactions.

How to Store and Dispose of Phthalazolum

Storage and disposal instructions for Phthalazolum (Phthalylsulfathiazole) tablets are set by regulatory documents to ensure stability and safety.

Storage Conditions

Phthalazolum must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and stored in its original, tightly closed container. It is mandatory to keep this product out of the sight and reach of children and do not freeze the tablets.

Disposal Instructions

Do not use the medicine past the expiration date printed on the label. Unused or expired Phthalazolum should be discarded using an authorized drug take-back program. If a take-back program is not available, the tablets must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before disposal in the household trash. The tablets must not be flushed down a toilet or sink.